Analysis of treatment effect of three kinds of lipid-lowering drugs and blood lipid level in elderly patients with acute cerebral infarction complicated and hyperlipemia

Zhang Yun-shu[]

doi:10.3969/j.issn.1674-4055.2016.02.26

Abstract：Objective To study and analysis of the clinical effect of three kinds of lowering lipid-lowering drugs, which were used in the elderly patients with acute cerebral infarction and high blood fat.Methods 180 patients with senile atherosclerotic acute cerebral infarction and high cholesterol, and treated in neurology department of the Third Hospital of Shijiazhuang between 2014.02~2015.02 were selected. Patients were randomly divided into rosuvastatin group, simvastatin group and atorvastatin group. Each group has 60 patients. Besides regular treatment, rosuvastatin group was given rosuvastatin, simvastatin group was given simvastatin and atorvastatin group was given atorvastatin. The treatment maintained for 2 weeks. Triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), serum C reactive protein (CRP) and interleukin 6 (IL-6), tumor necrosis factor - alpha (TNF alpha), serum creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and National Institutes of Health Stroke Scale (NIHSS) were test before and after treatment.Results After 2 weeks of treatment, TG, TC, HDL-C, LDL-C, CRP, IL-6, TNF-ɑ levels in all patients were significantly improved than the time of admission (P<0.05). TG, TC, LDL-C, CRP, IL-6 and TNF-ɑ in rosuvastatin group was significantly lower, and HDL-C levels was significantly higher than other two groups. CRP, TNF-ɑ in atorvastatin group was significantly lower than simvastatin group (P<0.05). NIHSS score was significantly reduced in all patients at one month after treatment (P<0.05). NIHSS scores in rosuvastatin group were significantly lower than the simvastatin group and atorvastatin group (P<0.05). Conclusion Rosuvastatin, simvastatin and atorvastatin were safety and have good lipid-lowering effect. But rosuvastatin is better than other two drugs in acute phase inflammatory response and neurological deficit symptoms improvement, as well as lipid-lowering effect.